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Abstract 
Excessive medication intake is a risk factor for the development of Medication-
Overuse Headache (MOH), a condition characterized by an increase of headache 
frequency to a daily or near-daily pattern. As yet, it is largely unknown why some 
patients overuse medication. In this study, we examined to what extent attitudes 
about pain medication, especially perceived need and concerns, and problem 
solving are related to MOH. Patients with migraine (N=133) and MOH with a 
history of migraine (N=42) were recruited from a tertiary headache referral center 
and completed questionnaires measuring problem solving and attitudes about 
pain medication. A problem solving mode aimed at solving pain was associated 
with a higher need for and concerns about medication intake. Interestingly, in a 
model accounting for demographic factors and pain intensity, attempts to control 
pain, need for medication and concerns about scrutiny by others because of 
medication intake all had a unique value in accounting for MOH. Results are 
discussed in terms of how repeated attempts to solve pain may trigger overuse of 
medication, even in the presence of clear negative consequences.  
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1. Introduction 
Acute and preventive pharmacological treatment has proven effective in 
reducing the frequency, severity and duration of migraine attacks [47,48,51]. 
However, overuse of acute medication may bring along negative consequences, 
and eventually result in Medication-Overuse Headache (MOH) [12]. This is a 
disorder characterized by increased headache frequency up to a daily or almost 
daily pattern [47]. The prevalence rates of MOH across different European 
countries range from 0,7 to 1,7% [1,7,50,54,57]. In tertiary care, up to 30% of 
patients in Europe and more than 50% in the USA present with MOH 
[5,27,36,46]. MOH may have severe effects on quality of life [4,55]. 
To date, it remains unclear why some patients overuse medication. 
Functional and structural changes in the brain may be involved in the 
development of MOH [14,51], and explain why MOH occurs frequently in patients 
with episodic migraine [4,7,12]. However, a largely neglected issue relates to the 
psychological determinants of medication use. According to Horne and Weinman 
[26], medication intake depends upon a cost-benefit analysis of the need for 
medication against its perceived costs. In particular, increasing medication use 
may be beneficial in reducing the pain temporarily, but may also lead to obvious 
costs such as somatic, neurological and/or psychological complications 
[15,16,34,44]. When such negative effects prevail, Horne and Weinman [26] 
would predict a decrease of medication intake. However, this does not seem to 
be the case in patients with MOH. It seems that those patients are inclined to 
medication overuse despite being aware of its negative consequences [51]. Even 
after a successful treatment, most often consisting of psycho-education and a 
withdrawal protocol, the relapse rate is about 25-30% [19,30,31,40].  
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In an attempt to further our understanding of this apparently paradoxical 
behavior in MOH, we adopt a functional coping perspective [13,52] that is based 
upon the Dual Process Model of coping [6]. According to this model, there are two 
modes of coping with adversity, such as pain: assimilative and accommodative 
coping. When pain interferes with valued activities [28], patients in  the 
assimilative mode focus their attention and efforts upon solving pain, such as by 
taking medication, in order to resume daily life. In the accommodative mode, 
patients disengage from persistent attempts to solve pain, and (re-) engage in the 
pursuit of valued life goals that are less affected by their pain. Often patients are 
then more willing to accept that there is no solution, and that pain will last for a 
longer duration. It has been proposed that many patients with chronic pain 
become stuck in the assimilative mode, and thus persevere in attempting to solve 
an insoluble problem [13,52]. Such ineffective problem solving fuels and 
exacerbates hypervigilance, distress and disability [8, 9].  
Building upon these arguments, we expect that patients with MOH will 
more frequently adopt an assimilative coping mode than patients with episodic 
migraine. Related, we expect that, in comparison with patients with episodic 
migraine, MOH patients believe to be in more need for medication to control their 
pain, despite being aware and concerned about its negative consequences. 
 
2. Method  
2.1. Participants 
The study was approved by the Medical Ethics Committee of the Ghent 
University Hospital, Belgium. Participants were recruited from the Headache 
Clinic of the Department of Neurology at the Ghent University Hospital: 490 
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consecutive patients with an episodic migraine diagnosis, or with a diagnosis of 
MOH with a history of migraine, were invited by their treating physician at the 
Headache Clinic. They received a letter containing information about the study, 
an informed consent letter and the questionnaires. When patients consented to 
participate, they signed the informed consent letter, filled out the questionnaires 
at home and sent both back to the Headache clinic by regular mail.  
Migraine diagnosis was consistent with the criteria of the International 
Headache Society (IHS) [24]. The diagnosis of MOH was based upon the revised 
ICHD-II criteria, proposed by the IHS [25]. According to these criteria, MOH is 
diagnosed in patients who report headache on ≥15 days/month for >3 months 
and who use ergotamine, triptans, or combination analgesics on ≥10 days/month, 
or simple analgesics or any combination of ergotamine, triptans, analgesics and 
opioids on ≥15 days/month. One hundred and eighty eight patients returned the 
questionnaires (38%). Compared to a complete patient database that has been 
held in the Headache Clinic of the Department of Neurology since October 2004 
and in which the overall ratio of migraine over MOH was 2.8 (73% migraine 
patients, 27% MOH), we found no differential response rate between patients with 
migraine and MOH patients in the present study (76% migraine patients, 24% 
MOH). No data are available on those patients who failed to complete the 
questionnaires. Subsequently, headache classification was double-checked by 
one of the authors (KP). Based on a verification of headache diagnosis, thirteen 
patients were excluded, resulting in a final sample of 175 patients.  
The sample of migraine patients comprised of 133 patients (84.2% 
female), aged between 17 and 68 (mean age = 38.86 years, SD = 12.04). 
Further, 63.4% had a higher education (longer than the age of 18 years). More 
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than half of the patients (67.7%) was in paid employment, whilst only 4.8% 
received state supported income replacement because of their pain.  
The MOH sample consisted of 42 patients (83.3% female), aged between 
23 and 75 years (mean age = 45.57 years, SD = 11.45). Approximately half of the 
patients (45.2%) had a higher education (longer than the age of 18 years). 
Further, 65.8% was working and 7.9% was recipient of disablement insurance 
benefits. Of the total MOH sample, 7 patients fulfilled the ICHD- II criteria [25] of 
analgesic-overuse headache, 4 patients those of triptan-overuse headache and 2 
patients those of opioid-overuse headache. The other 29 MOH patients could not 
be subclassified as they used at least 2 classes of medications. 
 
2.2.  Measures 
 2.2.1.  Medication intake 
Information was collected about medication intake during the past three 
months. Patients were asked to indicate on how many days during the past three 
months they had been using pain medication. Patients were also asked to report 
about the names of the pain medication they used, the exact dose and daily and 
monthly frequency of intake of each individual medication. The medication 
information was used to calculate the different classes of medications and the 
number of active constituents being taken for pain. Active constituents were 
classified as ergotamine, triptans, simple analgesics (NSAID’s, acetylsalicylic 
acid, paracetamol), opioids, barbiturates or coffeine. 
2.2.2. Pain frequency, pain intensity and disability  
The Migraine Disability Assessment Questionnaire (MIDAS) [49] measures 
headache-related disability, frequency of headaches and the intensity of 
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headache pain. Headache-related disability during the past three months is 
measured by means of five disability questions. Patients record the number of 
missed days due to headache on three questions concerning school or paid work 
(“On how many days in the last 3 months did you miss work or school because of 
your headaches?”), household work (“On how many days in the last 3 months did 
you not do household work because of your headaches?”) and family, social or 
leisure activities (“On how many days in the last 3 months did you miss family, 
social, or leisure activities because of your headaches?”). Two further questions 
assess the number of additional days with significant limitations to activity 
(defined as at least 50% reduced productivity) in the domains of employment 
(“How many days in the last 3 months was your productivity at work or school 
reduced by half or more because of your headaches?”) and household work 
(“How many days in the last 3 months was your productivity in household work 
reduced by half or more because of your headaches?”). Disability is assessed as 
the sum of lost days due to headache recorded for all of the above questions. 
Two additional questions assessed the frequency of headaches (“On how many 
days in the last 3 months did you have any headache (if a headache lasted more 
than one day, count each day)?”) and the intensity of the headache pain (“On a 
scale from 0 to 10, on average how painful were these headaches?”). The latter 
question is scored on a 11-point scale, ranging from 0, no pain at all, to 10, pain 
is as bad as it can be. The MIDAS has demonstrated good reliability and validity 
[49]. Cronbach’s alpha for the summed disability measure in this study was α = 
.85. 
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2.2.3. Problem Solving and acceptance  
The Pain Solutions Questionnaire (PaSol) [11] measures efforts at 
changing, solving or accepting pain and the problems associated with pain. The 
PaSol has 14 items grouped into four interrelated scales: (1) Solving Pain scale 
(4 items; e.g., “I try everything to get rid of my pain”), (2) Meaningfulness of Life 
Despite Pain scale (5 items; e.g., “Even when I have severe pain, I still find my 
life meaningful”), (3) Acceptance of the Insolubility of Pain scale (3 items; e.g., “I 
can live with the idea that there is no solution for my pain”), and (4) Belief in a 
Solution scale (2 items; e.g., “I am convinced that there is a treatment for my 
pain”). Whereas the ‘Solving Pain’ subscale is an indicator of a problem solving or 
assimilative approach, both the ‘Meaningfulness of life despite pain’ and 
‘Acceptance of the insolubility of pain’ subscales represent the accommodative 
mode of coping. Each item is answered on a 7-point Likert scale, ranging from 0, 
not at all applicable, to 6, highly applicable. The PaSol has demonstrated good 
reliability and validity [11]. Cronbach’s alpha’s in this study ranged from .82 to .88.   
2.2.4. Attitudes about pain medication  
The Pain Medication and Attitudes Questionnaire (PMAQ) [37] assesses 
perceived need and concerns held by patients regarding their use of medication.  
The PMAQ has 47 items grouped into seven scales: (1) Addiction (5 items; e.g., “I 
worry about becoming addicted to my pain medication/s”), (2) Need (8 items; e.g., 
“I rely on my pain medication/s”), (3) Scrutiny (8 items; e.g., “I worry about how 
other people view my use of pain medication/s”), (4) Side effects (7 items; e.g., “I 
have concerns about the side effects from my pain medication/s”), (5) Tolerance 
(6 items; e.g., “I worry that over time I will need more pain medication/s”), (6) 
Mistrust of doctors (7 items; e.g., “I worry that I have been told different 
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information about my pain medication/s by different doctors”), and (7) Withdrawal 
(6 items; e.g. “I worry that I will have some withdrawal symptoms if I stop my 
medication”).  Each item is answered on a 6-point Likert scale, ranging from 0, 
never true, to 6, always true. The PMAQ has demonstrated good reliability and 
validity [37]. Cronbach’s alpha’s in this study ranged from .64 (Mistrust of doctors) 
to .91 (Addiction).  
 
2.3. Data - Analytical strategy 
Statistical analyses were performed using SPSS 15.0 for Windows. First, 
descriptive statistics were calculated to investigate differences in pain frequency, 
pain intensity, disability and intake of medication between the two patient groups. 
Correlational analyses were carried out in order to examine the relations of 
problem solving and acceptance with attitudes about pain medication. Second, 
the value of demographic variables, pain intensity, problem solving, acceptance 
and attitudes about pain medication in explaining Medication-Overuse Headache 
were assessed by means of separate univariate logistic regression analyses. 
Finally, we investigated the unique value of problem solving and attitudes about 
pain medication in explaining Medication-Overuse Headache using a multivariate 
logistic regression analysis, while accounting for the effects of demographic 
variables and pain intensity.  
 
3.  Results 
3.1.  Descriptive and Correlational Statistics 
A series of t-tests for independent samples was used to assess differences 
in pain frequency, pain intensity, headache-related disability, and amount of 
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active constituents taken between the two patient groups. Whenever the 
assumption of normality was violated, the Mann-Whitney U statistic instead of the 
Student t-statistic was used. MOH patients reported more frequent headaches (u 
= 832.5, p < .001, d = -1.54) and more intense pain (t(166) = 1.79, p < .05, d = 
0.33) compared to migraine patients. No significant differences in headache-
related disability were found (u = 1549, ns, d = -0.32). Furthermore, analyses 
revealed significant differences in the number of active constituents taken 
(t(55.271) = -4.29, p < .001, d = -0.89), with MOH patients taking a greater 
number of active constituents (M = 3.36, SD = 1.67) compared to migraine 
patients (M = 2.17, SD = 1.21). Furthermore, we analysed whether there was a 
significant difference in the proportion of patients who had a higher education 
between the migraine and the MOH sample (63.4% versus 45.2%). The chi-
square test just failed significance (χ² (1) = 3.87, p = .05). 
Chi-square tests and Fisher’s exact test were used to assess differences in 
the distribution of medication type intake between both patient groups (see Table 
1). The intake of opioids (χ2 (1) = 18.52, p<.001) and preparations containing 
coffeine (χ2 (1) = 7.27, p<.01) was found to be higher in MOH patients compared 
to migraine patients. Fisher’s exact test comparing ergotamine intake between 
patient groups reached significance (p = .06). No significant differences were 
found concerning the intake of triptans (χ2 (1) = 0.01, ns) and analgesics (χ2 (1) = 
0.02, ns). Within the entire sample, there were no patients taking barbiturates.  
< Table 1 about here > 
Correlational analyses were carried out in order to examine the relations of 
problem solving and acceptance with attitudes about pain medication. 
Interestingly, solving pain was positively related to perceived need for medication 
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(r=.30, p < .001), to concerns about tolerance (r=.26, p < .01) and withdrawal 
(r=.15, p < .05) . Acceptance of the insolubility of pain showed moderate negative 
associations with concerns about scrutiny (r=-.26, p < .01), tolerance (r=-.17, p < 
.05) and withdrawal (r=-.16, p < .05). Meaningfulness of life despite pain was 
negatively related both to perceived need for medication (r=-.27, p < .001) and to 
concerns about addiction (r=-.24, p < .01), scrutiny (r=-.35, p < .001), tolerance 
(r=-.26, p < .01), mistrust of doctors (r=-.30, p < .001) and withdrawal (r=-.34, p < 
.001). Lastly, belief in a solution was negatively related to concerns about scrutiny 
(r=-.25, p < .01), tolerance (r=-.16, p < .05) and mistrust of doctors (r=-.31, p < 
.001).  
 
3.2.  Value of demographic variables, pain intensity, problem solving, 
acceptance  and attitudes about pain medication in explaining Medication-
Overuse Headache 
First, a series of separate univariate logistic regression analyses were 
performed to investigate the value of age, gender (0 = male; 1 = female), pain 
intensity, problem solving, acceptance and attitudes about pain medication in 
explaining Medication-Overuse Headache (0 = migraine; 1 = MOH). Table 2 
summarizes the results of these analyses. As expected, MOH was significantly 
associated with a higher age. No association was found between pain intensity 
and MOH diagnosis. Furthermore, the values of OR indicated that an increase of 
one unit on solving pain increased the odds of being diagnosed with MOH 
(relative to being diagnosed with migraine) with a factor of 1.14 [18]. Also, an 
increase of one unit on meaningfulness of life despite pain decreased the odds of 
being diagnosed with MOH with a factor of 0.95. Finally, need for medication and 
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all concerns about pain medication had significant value in explaining MOH, with 
OR’s ranging from 1.10 to 1.24. 
Second, a multivariate logistic regression analysis was executed to 
investigate the unique value of problem solving and attitudes about pain 
medication in explaining Medication-Overuse Headache, while accounting for the 
effects of demographic variables and pain intensity. Variance-inflation factors 
suggested that there was no problem of collinearity. As shown in Table 2, need 
for medication had a significant value in explaining MOH diagnosis: an increase 
of one unit on need for medication increased the odds of being diagnosed with 
MOH with a factor of 1.24. Furthermore, scrutiny also made a significant 
contribution in explaining MOH. Results showed that an increase of one unit in 
experiencing unfavourable scrutiny by others because of medication intake 
increased the odds of being diagnosed with MOH with a factor of 1.12. 
Interestingly, solving pain had unique value in accounting for MOH diagnosis. The 
OR showed that an increase of one unit on solving pain increased the odds of 
being diagnosed with MOH with a factor of 1.23.  
< Table 2 about here > 
 
4.   Discussion 
The present study aimed at clarifying the role of problem solving 
(assimilative coping mode) and beliefs about pain medication in relationship to 
MOH. The results can be readily summarized. First, an assimilative coping mode 
aimed at solving pain was related to a higher perceived need for medication and 
higher levels of concerns about tolerance to medication and withdrawal 
symptoms. Second, attempts to solve pain, need for medication and concerns 
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about pain medication were positively related to MOH. Third, after controlling for 
demographic variables and pain intensity, attempts to solve pain, need for 
medication and concerns about unfavorable scrutiny by others were found to 
have unique value in explaining MOH.  
Of particular interest to this study was the finding that a problem solving 
mode aiming at pain control was uniquely related to MOH. Correlational analyses 
further showed that attempts at solving pain were related to a higher perceived 
need for medication and higher levels of concerns about tolerance and 
withdrawal. This is in line with earlier findings in which patients with MOH were 
found to have a negative attitude towards analgesics but believed that they could 
not cope without [22]. Our findings point out that patients who frame the problem 
of pain as one that has to be solved, may be at a higher risk of developing MOH. 
The role of solving pain, as an indicator of assimilative coping, is in line with the 
Dual Process Model of coping as outlined by Brandstädter and Renner [6]. A 
problem approach that is characterized by persistent attempts to solve the pain 
may increase the need for medication, despite clear negative consequences. An 
important issue pertains to the reasons for this behavioural pattern. There are at 
least two possible reasons. First, the pain relieving effect of the medication in the 
short term may be more salient than its long-term negative consequences. As 
such, it may provide a sense of control over pain that is not easily relinquished. 
Second, it may be that the ongoing activities and goals that are interrupted by 
pain are of central importance in a patient’s life. A patient may then prefer to 
search for a solution instead of giving up highly valued goals [52]. Paradoxically, 
a focus on solving pain may inadvertently heighten attention to pain and may add 
to the problem. This mechanism may partially explain why some MOH patients 
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persevere in using medication, and relapse in medication overuse after 
successful withdrawal. In accordance with this line of reasoning is the finding that 
patients reporting their life as meaningful despite the pain, were less likely being 
diagnosed with MOH. These patients may have been successful in adapting their 
goals in a way that pain interferes less with goal attainment [52]. 
Although univariate regression analyses showed that all medication 
concerns were positively related to MOH, only concerns about unfavorable 
scrutiny by others had unique value in explaining MOH. This is in line with the 
findings of McCracken and colleagues [37], who found that overuse was 
predominantly predicted by perceiving medication as needed and secondarily 
related to concern about negative scrutiny in chronic pain patients. It is possible 
that patients overusing their medication become ashamed and embarrassed 
because they cannot maintain an optimal level of dosing. 
Our results argue for an action-oriented and goal-dependent theory that 
allows us to gain insight into how patients deal with the interference of life 
activities by persistent headache. This view may complement other explanations 
of MOH. For example, some studies focus upon an addiction or dependence 
component in a subgroup of MOH patients. Indeed, some drugs taken by patients 
contain substances with psychotropic effects, i.e. barbiturates, opioids, and 
caffeine [17,35,41,42]. Although some patients may be classified as addicted to 
their medication, this may not apply to all patients. First, there is still some doubt 
whether drugs like triptans and simple analgesics may result in pharmacological 
dependence [14]. Second, some studies did not find any difference in self-
reported dependence-related behavior between patients with MOH on the one 
hand and patients with episodic migraine and healthy individuals on the other 
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hand [45]. Third, the uncritical use of the DSM-IV or ICD-10 criteria for substance-
related disorders in patients with MOH, may result in an inflation of cases. MOH 
patients with long-term drug use may easily fulfill some of the defining features of 
addiction, such as tolerance, withdrawal symptoms, use of medication in a larger 
amount or for a longer period than intended, unsuccessful efforts to cut down or 
control the use despite harmful consequences and a high priority given to drug 
use [2,56]. However, often overlooked is that for a diagnosis of addiction, drug 
use needs to be associated with a progressive increase of time in obtaining or 
taking the drug or an increased recovery from the effects of the drug. Moreover, 
addiction is often characterized by a progressive neglect of alternative pleasures 
or interests because of drug use and may result in a reduction of social, 
occupational or recreational activities. This is often not the case in MOH patients. 
Instead, our results may point out that MOH patients overuse their medication in 
order to retain functioning. Further studies are needed to validly assess the 
relative contribution of dependence in MOH. A recent PET study, for example, 
showed hypo-function in the orbitofrontal cortex, a brain region known for its role 
in substance dependence, after 3 weeks drug withdrawal, but more so in patients 
overusing combination analgesics [21]. Besides neuroimaging data, recent 
neurobiological and pharmacogenetic studies appear to support the existence of 
dependence in some patients with MOH (for an overview, see Radat et al. [43]). 
This all might reflect an underlying susceptibility predisposing specific subgroups 
of MOH patients to substance dependence.  
The results of this study may have a number of implications. When pain 
blocks valued goals, patients may be highly motivated to solve or control their 
pain, and may engage in medication use, despite clear negative consequences 
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and risks. As a consequence, withdrawal of medication, commonly accepted as 
the first and primordial step in treating MOH [5,39], may only be partially effective 
in those patients. At least, education of patients about the problem seems to be 
an important treatment component [10,14,51]. Additionally, some patients may 
benefit from techniques within traditional programs of cognitive behavioral therapy 
aimed at increasing problem solving skills and changing the functional approach 
to pain in order to cope more effectively with disability, discomfort and distress [3, 
20]. Such techniques may be compatible with the therapeutic approach of 
‘acceptance’ in behavior therapy [23,38]. Within the pain literature, acceptance 
refers to “… a willingness to experience continuing pain without needing to 
reduce, avoid or otherwise change it” [38]. Similar to acceptance, we found that a 
coping mode directed at relinquishing pain control was associated with less need 
for medication, less concerns about intake and an overall lesser chance of being 
diagnosed with MOH. Still, these results are preliminary and further studies 
examining the effects of ‘acceptance’ of pain in chronic headache samples are 
awaiting. Lastly, effective preventive medication in order to treat the underlying 
migraine condition and reduce the number of headache attacks and/or the early 
assessment of behavioral and psychological co-factors are recommended 
[14,29,33,39].     
 This study has a number of limitations, each of which point to directions for 
future research. First, all findings are based on cross-sectional and correlational 
data. No causal interpretations about the order of relationships can be made. 
Studies with longitudinal designs are needed to provide evidence on the temporal 
relations between the variables. Second, the overall response rate was relatively 
low. We believe that the main reason is to be found in the use of a strict 
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recruitment protocol in which all consecutive patients from a headache clinic were 
invited. Nevertheless, more studies are needed, and our results need to be 
confirmed by large-scale studies. Third, the assessment of variables in this study 
relied on patient self-report. Further research may benefit from the adaptation of  
experimental paradigms designed to measure (correlates of) problem solving 
behaviour [53]. A fourth limitation is that the mechanism we propose is probably 
not the only one contributing to the problem of MOH. Overall, observed effects in 
this study were relatively small, leaving a substantial amount of variance 
unexplained. More research is needed on the interplay between the somatic 
pathophysiology, such as the role of genetic susceptibility and endocrine and 
neurotransmitter function (for an overview, see Evers et al. [14]), and the 
psychological mechanisms underlying MOH. Lastly, we performed no subgroup 
analyses according to the type of overused medication among the patients with 
MOH. However, the development of the disorder and prognosis after withdrawal 
seem to be dependent upon which type of medication patients are overusing 
[31,32]. In general, more research is needed that could unravel the relative 
contribution of diverse psychological mechanisms, such as substance 
dependence and a functional coping perspective. It would, for example, be 
particularly helpful to study the contributing factors to relapse after successful 
withdrawal in different subgroups of MOH patients and to test these findings in 
prospective studies. 
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Table 1 
Percentages of medication type intake in patients with migraine and MOH 
 
 Migraine 
(N=133) 
MOH 
(N=42) 
 
Ergotamine 
 
3.8% 
 
 
11.9%(*) 
Triptans 57.9% 57.1% 
 
Simple analgesics 84.2% 83.3% 
 
Opioids 9.8% 38.1%*** 
 
Barbiturates 0% 0% 
 
Coffeïne 9.8%) 26.2%** 
p < .05*; p <.01**; p <.001** 
 
 
 
 
 
 
Table 2. 
Summary of the univariate and multivariate logistic regression analyses with 
diagnosis (0=migraine; 1=MOH) as dependent variable and demographic 
variables, pain intensity, problem solving, acceptance and attitudes about pain 
medication as independent variables.  
Criterium variable Predictor Univariate analysis Multivariate analysisa 
  OR [95%CI] OR [95%CI] 
Diagnosis Age 
Gender 
Pain intensity 
Solving pain 
Meaningfulness 
Acceptance 
Belief 
Addiction 
Need 
Scrutiny 
Side effects 
Tolerance 
Mistrust of doctors  
Withdrawal 
1.05**    
1.07       
0.84       
1.14*     
0.95*     
1.00      
0.95      
1.20***  
1.24***  
1.14***  
1.10**   
1.12***  
1.12**   
1.17*** 
[1.02-1.08] 
[0.42-2.72] 
[0.69-1.02] 
[1.02-1.29] 
[0.91-0.99] 
[0.93-1.07] 
[0.86-1.05] 
[1.12-1.27] 
[1.15-1.34] 
[1.08-1.20] 
[1.04-1.16] 
[1.05-1.18] 
[1.03-1.22] 
[1.10-1.24] 
1.03 
0.54 
0.82 
1.23* 
0.96 
1.07  
1.10  
1.09  
1.24** 
1.12* 
0.93 
0.90 
1.12  
1.05 
[0.98-1.09] 
[0.11-2.72] 
[0.61-1.12] 
[1.01-1.50] 
[0.86-1.07] 
[0.92-1.23] 
[0.90-1.35] 
[0.96-1.24] 
[1.08-1.42] 
[1.01-1.24] 
[0.83-1.05] 
[0.81-1.01] 
[0.97-1.28] 
[0.95-1.17] 
Notes. a χ2(14) = 73.628, p < .001; .38 (Cox & Snell); .57 (Nagelkerke); 95% CI = 95% Confidence 
Interval; OR = odds ratio, an OR > 1 reflects a higher probability of MOH and an OR < 1 reflects a 
lower probability of MOH, compared to episodic migraine  
* p < .05; ** p < .01; *** p < .001 
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